This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

1 Jun 2017

Hikma signs an exclusive license and supply agreement with Octapharma for Octaplex

Deal adds the first plasma-derived treatment to Hima's product offering.

Hikma Pharmaceuticals has signed an exclusive license and supply agreement with Octapharma for Octaplex, a leading four-factor prothrombin complex concentrate (PCC). Octaplex provides a balanced content of coagulation factors II, VII, IX, X and of protein C and S. Octaplex is a recommended therapy for prophylaxis and treatment of bleeding in acquired or congenital coagulation disorders associated with deficiency of the prothrombin complex factors.

Under the terms of the agreement, Hikma will have the exclusive rights to register, distribute and market Octaplex in major countries across MENA, leveraging Hikma’s strong local presence, sales and marketing capabilities and regulatory expertise.

Mazen Darwazah, Vice Chairman and CEO of MENA and Emerging Markets said: “We are delighted to be partnering with Octapharma, one of the largest human protein manufacturers in the world, to enhance our growing portfolio of innovative, high value products in the MENA and add the first plasma derived treatment to our product offering. Bringing this life-saving product to the region reinforces our commitment to increasing patients’ access to high-quality medicines.”

Related News